Pharmafile Logo
Pharmafocus logo
Advanced Search

Bydureon

Showing 8 posts of 8 posts found.

astrazeneca_building_white

AstraZeneca’s once-weekly auto-injector Bydureon BCise wins EU approval in type 2 diabetes

August 30, 2018
Research and Development, Sales and Marketing AstraZeneca, Bydureon, EU, Europe, diabetes, pharma, type 2 diabetes

AstraZeneca has announced that its auto-injector Bydureon BCise (exenatide 2mg prolonged-release suspension) has been approved by the European Commission for …

News
GSK image

Europe grants Eperzan licence

March 27, 2014
Sales and Marketing Bydureon, GSK, diabetes, eperzan, lilly

The European Commission has granted marketing authorisation to GlaxoSmithKline’s new diabetes treatment Eperzan – setting the manufacturer on a collision …

News

Amylin withheld safety data, says FDA

June 27, 2012
Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, FDA, lilly

The US medicines regulator says Amylin held back data relating to the safety of its diabetes drug Bydureon. The allegation …

News
GSK image

GSK’s diabetes drug misses goal

April 4, 2012
Research and Development, Sales and Marketing Bydureon, GSK, Victoza, albiglutide, diabetes

GlaxoSmithKline has insisted its new long-acting Type 2 diabetes drug albiglutide remains on course for filing following topline results from …

News

Amylin dismisses BMS acquisition deal

March 30, 2012
Manufacturing and Production, Sales and Marketing Amylin, BMS, Bydureon, diabetes, lilly

Amylin Pharmaceuticals has rebuffed a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb, according to reports. Shares in Amylin rose …

News
Lilly HQ picture

Amylin to pay up to $1.6 billion to sever ties with Lilly

November 8, 2011
Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, R&D, lilly

Amylin will pay up to $1.6 billion to end its diabetes pact with Lilly after a difficult year for the …

News
Byetta

NICE recommends Lilly’s long-acting Bydureon

October 18, 2011
Sales and Marketing Bydureon, NICE, diabetes

NICE has recommended Eli Lilly’s long-acting diabetes drug Bydureon after the failure of oral treatments. Bydureon (exenatide) – a long-acting …

News
Byetta

FDA questions delay long-acting Byetta

March 17, 2010
Manufacturing and Production Bydureon, Byetta, Syncria, Victoza

A once-weekly formulation of Eli Lilly and Amylin Pharmaceuticals’ blockbuster diabetes medication Byetta has hit a manufacturing hurdle en route …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025